School of Medicine Faculty
Associate Professor of Pharmacology
University of Arizona
David Gortler's research examines atherosclerosis, atheroprogression,
cholesterol metabolism (including: statin pharmacology and lipid/ LDL/
HDL modulation) and obesity. Dr. Gortler is proficient in the drug development
process, the drug approval process, clinical trial design, and is a drug expert
and an expert in the FDA review process. Among other reviews, Dr. Gortler was
the lead FDA expert and lead clinical reviewer for the Merck SEARCH Trial which
compared the safety and efficacy of simvastatin 80mg to simvastatin 20mg. Prior
to joining Georgetown, Dr. Gortler was an Assistant Professor of Pharmacology at
Yale University, and prior to that he was an Investigational Medicine Scientist
at Pfizer Inc.
Coronary Artery Patient Coronary Artery
Gortler D, Schlösser FJ, Muhs BE, Nelson MA,
Periprocedural drug therapy in carotid artery stenting: the
need for more evidence. Vascular.
Gortler D, Maloney S, Rutland R, Westvik T,
Muto A, Kudo FA, Dardik A.
Adjunctive pharmacologic use in carotid endarterectomy: a
Haga M, Chen A, Gortler D, Dardik A, Sumpio
Shear stress and cyclic strain may suppress apoptosis in
endothelial cells by different pathways.
Kilaru S, Frangos SG, Chen AH, Gortler D,
Dhadwal AK, Araim O, Sumpio BE.
Nicotine: a review of its role in atherosclerosis.
J Am Coll Surg.
Chen AH, Gortler DS, Kilaru S, Araim O,
Frangos SG, Sumpio BE.
Cyclic strain activates the pro-survival Akt protein kinase
in bovine aortic smooth muscle cells.
Surgery. 130(2):378-81, 2001
Medline Publications and
Click here for publicly available full text articles by David
"Frontiers in Medicine" article and profile for David Gortler
Click here to do a Medline Search for all publications of David Gortler